| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 14/06/2024 | 23:41 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 14/06/2024 | 22:00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 05/06/2024 | 23:11 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 31/05/2024 | 00:01 | PR Newswire (US) | Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib) | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 23/05/2024 | 23:05 | PR Newswire (US) | Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 06/05/2024 | 22:01 | PR Newswire (US) | Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 02/05/2024 | 13:00 | PR Newswire (US) | Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 18/04/2024 | 14:00 | PR Newswire (US) | Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 11/04/2024 | 14:00 | PR Newswire (US) | Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 23/02/2024 | 14:00 | PR Newswire (US) | Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 16/02/2024 | 22:40 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 15/02/2024 | 23:26 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 15/02/2024 | 13:00 | PR Newswire (US) | Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 01/02/2024 | 14:00 | PR Newswire (US) | Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 08/01/2024 | 14:00 | PR Newswire (US) | Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 18/12/2023 | 14:00 | PR Newswire (US) | Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 12/12/2023 | 14:05 | PR Newswire (US) | Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 09/12/2023 | 18:30 | PR Newswire (US) | Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 28/11/2023 | 14:00 | PR Newswire (US) | Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 10/11/2023 | 14:00 | PR Newswire (US) | Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 26/10/2023 | 22:01 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 26/10/2023 | 13:00 | PR Newswire (US) | Blueprint Medicines Reports Third Quarter 2023 Results | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 23/10/2023 | 14:30 | PR Newswire (US) | Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 12/10/2023 | 14:00 | PR Newswire (US) | Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023 | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 02/08/2023 | 13:00 | PR Newswire (US) | Blueprint Medicines Reports Second Quarter 2023 Results | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 19/07/2023 | 14:00 | PR Newswire (US) | Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023 | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 30/06/2023 | 12:08 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 24/06/2023 | 01:08 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 03/06/2023 | 15:00 | PR Newswire (US) | Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting | NASDAQ:BPMC | Blueprint Medicines Corporation |
| 23/05/2023 | 16:00 | PR Newswire (US) | NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis | NASDAQ:BPMC | Blueprint Medicines Corporation |